In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Metagenomi Inc (NASDAQ: MGX) closed at $3.19 up 8.14% from its previous closing price of $2.95. In other words, the price has increased by $8.14 from its previous closing price. On the day, 1.83 million shares were traded. MGX stock price reached its highest trading level at $3.28 during the session, while it also had its lowest trading level at $2.88.
Ratios:
For a deeper understanding of Metagenomi Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.36 and its Current Ratio is at 6.36. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on May 07, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On May 02, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $16 to $6.
On March 05, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $25.Wells Fargo initiated its Overweight rating on March 05, 2024, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 11 ’25 when Noonberg Sarah B. bought 35,832 shares for $1.90 per share.
Sebastian Bernales bought 769,845 shares of MGX for $1,470,404 on Jul 09 ’25. On Jun 06 ’25, another insider, Wein Matthew, who serves as the insider of the company, sold 199 shares for $1.75 each. As a result, the insider received 348 and left with 16,693 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGX now has a Market Capitalization of 119730704 and an Enterprise Value of -42272296. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.55 while its Price-to-Book (P/B) ratio in mrq is 0.61. Its current Enterprise Value per Revenue stands at -1.252 whereas that against EBITDA is 0.49.
Stock Price History:
The Beta on a monthly basis for MGX is 0.13, which has changed by 0.6614584 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, MGX has reached a high of $4.92, while it has fallen to a 52-week low of $1.23. The 50-Day Moving Average of the stock is 53.57%, while the 200-Day Moving Average is calculated to be 53.05%.
Shares Statistics:
For the past three months, MGX has traded an average of 608.85K shares per day and 1283940 over the past ten days. A total of 37.53M shares are outstanding, with a floating share count of 26.07M. Insiders hold about 30.53% of the company’s shares, while institutions hold 19.88% stake in the company. Shares short for MGX as of 1757894400 were 1094418 with a Short Ratio of 1.80, compared to 1755216000 on 1496821. Therefore, it implies a Short% of Shares Outstanding of 1094418 and a Short% of Float of 4.0.
Earnings Estimates
The market rating for Metagenomi Inc (MGX) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.44 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$2.18 and -$2.34 for the fiscal current year, implying an average EPS of -$2.27. EPS for the following year is -$1.75, with 3.0 analysts recommending between -$1.2 and -$2.6.
Revenue Estimates
For the next quarter, 5 analysts are estimating revenue of $7.94M. There is a high estimate of $10M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 5 analysts have provided revenue estimates for MGX’s current fiscal year. The highest revenue estimate was $32.64M, while the lowest revenue estimate was $17.6M, resulting in an average revenue estimate of $28.37M. In the same quarter a year ago, actual revenue was $52.3MBased on 5 analysts’ estimates, the company’s revenue will be $28.04M in the next fiscal year. The high estimate is $40M and the low estimate is $10M.
